Background: The outbreak of SARS-CoV-2 abruptly disseminated in early 2020, overcoming the capacity of health systems to respond the pandemic. It was not until the vaccines were launched worldwide that an increase in survival was observed. The objectives of this study were to analyse the characteristics of survivors and their relationship with comorbidities. We had access to a database containing information on 16,747 hospitalized patients from Mexico, all infected with SARS-CoV-2, as part of a regular follow-up. The descriptive analysis looked for clusters of either success or failure. We categorized the samples into no comorbidities, or one and up to five coexisting with the infection. We performed a logistic regression test to ascertain what factors were more influential in survival. The main variable of interest was survival associated with multimorbidity factors. The database hosted information on hospitalized patients from Mexico between March 2020 through to April 2021. Categories 2 and 3 had the largest number of patients. Survival rates were higher in categories 0 (64.8%), 1 (57.5%) and 2 (51.6%). In total, 1741 (10.5%) patients were allocated to an ICU unit. Mechanical ventilators were used on 1415 patients, corresponding to 8.76%. Survival was recorded in 9575 patients, accounting for 57.2% of the sample population. Patients without comorbidities, younger people and women were more likely to survive.

Background The growing number of patients with complex clinical profiles has contributed to the increasingly deaths. The aim is to estimate survival and risk factors associated with hospitalized COVID-19 patients with multimorbidity in the state of Hidalgo, Mexico during 2020 to April 2021. Material and Methods An observational, longitudinal, prospective and analytical study was carried out in 11,955 hospitalized COVID-19 patients with multimorbidity from the Epidemiological Surveillance System for Respiratory Disease of Hidalgo. The variables of interest were survival of hospital stay per day and multimorbidity adjusted for age, sex, occupation, days of demand for care, and days of mechanical ventilation use. Kapplan-Meiner estimators, Log-Rank tests and Cox proportional hazard method were using. Results Hospitalized COVID-19 patients with multimorbidity survival was 53.5%. The probability of survival is reduced to 50% from day 17 of hospital stay. The shortest survival rate corresponds to cases with Hypertension + Chronic Kidney Disease (RR: 9.46, 95% CI 2.63-37.92), Diabetes + Hypertension + Chronic Kidney Disease (RR: 1.83, 95% CI 1.52-2.20), Diabetes + Hypertension + Obesity (RR: 1.35, 95% CI 1.16-1.57) and Diabetes + Hypertension (RR: 1.31, 95% CI 1.19-1.45). The use of mechanical ventilation for more than 14 days increases the survival rate (RR: 0.53, 95% CI 0.49-0.57). The survival rate from occupation increase in employees, students and health workers compared to the unemployed. Conclusions Multimorbidity increases the effect of the clinical and epidemiological interrelationships of the coexistence of multiple diseases in the same individual and reduces the survival of COVID-19 in hospitalized patients.